Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Soledad Molnar, MD, Victor J Jimenez Zepeda, Scott Van Wier, Esteban Braggio, Jonathan Keats, Michael Kuehl, Tammy Price-Troska, Greg Ahmann, Rachel Rempel, Kim Henderson, MD, S. Vincent Rajkumar, MD, Philip. R Greipp, MD, Daniel Auclair, John Carpten, Angela Baker, Keith Stewart, MD, P. Leif Bergsagel, MD, Wee Joo Chng, MD, Rafael Fonseca, MD

Blood (2008) 112 (11): 1663.

https://doi.org/10.1182/blood.V112.11.1663.1663

Published: 2008

Journal Articles

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

Wee J. Chng, MD, Marta Chesi, PhD, Tammy Price-Troska, Greg Ahmann, Kim Henderson, Philip Greipp, MD, Robert Kyle, MD, S. Vincent Rajkumar, MD, Morie Gertz, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD

Blood (2007) 110 (11): 241.

https://doi.org/10.1182/blood.V110.11.241.241

Published: 2007

Journal Articles

One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q.

Scott Van Wier, BS, Wee-Joo Chng, MD, Greg Ahmann, BS, Rachel Rempel, BS, Azzah Al Masri, Ph.D, Morie Gertz, MD, Angela Dispenzieri, MD, Philip Greipp, MD, Roelandt F.J. Schop, MD, Rafael Fonseca, MD

Blood (2005) 106 (11): 1546.

https://doi.org/10.1182/blood.V106.11.1546.1546

Published: 2005

Journal Articles

Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.

Morie Abraham Gertz, M.D., Martha Q. Lacy, M.D., Angela Dispenzieri, M.D., Philip R. Greipp, M.D., Mark R. Litzow, M.D., Kim J. Henderson, BA, Scott VanWier, BA, Greg Ahmann, BA, Rafael Fonseca, M.D.

Blood (2004) 104 (11): 4852.

https://doi.org/10.1182/blood.V104.11.4852.4852

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q.

Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q.

Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only